Sagimet Biosciences (STU:0O2) Future 3-5Y Total Revenue Growth Rate: N/A (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
36 GF Score
Price €7.78
GF Value €5.69
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sagimet Biosciences Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Sagimet Biosciences's Future 3-5Y Total Revenue Growth Rate is N/A.

Sagimet Biosciences  (STU:0O2) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Sagimet Biosciences Future 3-5Y Total Revenue Growth Rate Related Terms

STU:0O2 vs CABA, OVID, QTTB: Future 3-5Y Total Revenue Growth Rate Comparison

For the Biotechnology subindustry, Sagimet Biosciences's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences Future 3-5Y Total Revenue Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Future 3-5Y Total Revenue Growth Rate falls into.


STU:0O2
36GF Score
Sagimet Biosciences Inc STU:0O2
Future 3-5Y Total Revenue Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?

Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued. The current stock price of €7.78 is trading 36.7% above its estimated GF Value™ of €5.69. GuruFocus considers Sagimet Biosciences to be Significantly Overvalued.

Key valuation signals for STU:0O2:

  • Future 3-5Y Total Revenue Growth Rate: N/A
  • GF Value™: €5.69 vs. price of €7.78 (36.7% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
36GF Score

Get the complete analysis for STU:0O2

Future 3-5Y Total Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.78
Price
€5.69
GF Value